



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/535,814	03/28/2000	Yuh-Jiuan Lin	64,600-024 CIP	5514

7590 05/06/2002
Tung & Associates
838 West Long Lake Road
suite 120
Bloomfield Hills, MI 48302

EXAMINER

BRANNOCK, MICHAEL T

ART UNIT	PAPER NUMBER
----------	--------------

1646

DATE MAILED: 05/06/2002

16

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09535814			

EXAMINER	
Michael Brannock	
ART UNIT	PAPER NUMBER
1646	16

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

Applicant's response to the Office Action of 3/26/02 is noted, however, the reply filed on 4/22/02 is not fully responsive to the prior Office action because of the following matter(s): this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 as set forth previously. The raw sequence listing is not in a valid format. Please see attached CRF Problem report. Applicant is again encouraged to contact Mark Spencer @ 703 308-4212 for specific help in resolving this continuing problem.

Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. **EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).** Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the **SIX MONTH** statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael T. Brannock, Ph.D., whose telephone number is (703) 306-5876. The examiner can normally be reached on Mondays through Fridays from 9:00 a.m. to 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, Ph.D., can be reached at (703) 308-6564

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Michael T. Brannock
April 30, 2002

YVONNE EYLER, PH.D.
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Application No.: 09535814

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

These pages display submitted file 09/535,814C 2

SEQ ID NO:G1

Met Thr Glu Lys Asn Gln Thr Val Val Ser Glu Phe Val Leu Leu Gly Leu Pro Ile Asp Pro Asp
Gln Arg Asp Leu Phe Tyr Ala Leu Phe Leu Ala Met Tyr Val Thr Thr Ile Leu Gly Asn Leu Leu
Ile Ile Val Leu Ile Gln Leu Asp Ser His Leu His Thr Pro Met Tyr Leu Phe Leu Ser Asn Leu Ser
Phe Ser Asp Leu Cys Phe Ser Ser Val Thr Met Pro Lys Leu Leu Gln Asn Met Gln Ser Gln Val
Pro Ser Ile Pro Tyr Ala Gly Cys Leu Thr Gln Met Tyr Phe Phe Leu Phe Phe Gly Asp Leu Glu
Ser Phe Leu Leu Val Ala Met Ala Tyr Asp Arg Tyr Val Ala Ile Cys Phe Pro Leu His Tyr Thr
Thr Ile Met Ser Pro Lys Leu Cys Phe Ser Leu Leu Val Leu Ser Trp Val Leu Thr Met Phe His Ala
Val Leu His Thr Leu Leu Met Ala Arg Leu Cys Phe Cys Ala Asn Thr Ile Pro His Phe Phe Cys
Asp Met Ser Ala Leu Leu Lys Leu Ala Cys Ser Asp Thr Gln Val Asn Glu Leu Val Ile Phe Ile
Met Gly Gly Leu Ile Leu Val Ile Pro Phe Leu Leu Ile Ile Thr Ser Tyr Ala Arg Ile Val Ser Ser Ile
Leu Lys Val Pro Ser Ala Ile Gly Ile Cys Lys Val Phe Ser Thr Cys Gly Ser His Leu Ser Val Val
Ser Leu Phe Tyr Gly Thr Val Ile Gly Leu Tyr Leu Cys Pro Ser Ala Asn Asn Ser Thr Val Lys Glu
Thr Ile Met Ala Met Met Tyr Thr Val Val Thr Pro Met Leu Asn Pro Phe Ile Tyr Ser Leu Arg
Asn Lys Asp Met Lys Gly Ala Leu Arg Arg Val Ile Cys Arg Lys Lys Ile Thr Phe Ser Val

SEQ ID NO:G2

Asp-Pro-Asp-Gln-Arg-Asp-Cys

SEQ ID NO:G3

Leu-Phe-Leu-Ser-Asn-Leu-Ser-Phe-Ser-Asp-Leu-Cys-Ala

The file submitted is not a Sequence Listing.
Please see sample Sequence Listing (attached in
back) for valid format. Also, please consult
Sequence Rules.

SEQUENCE LISTING

SEQ ID NO:G1

LENGTH:313

ORGANISM:Canis familiaris

SEQUENCE:GP30955

DBSOURCE:Gswissprot: locus OLFD_CANFA, accession P30955

SEQ ID NOiG2
LENGTHiG7
TYPEiGPRT
ORGANISMiGCanis familiaris
SEQUENCEiGB1
Asp-Pro-Asp-Gln-Arg-Asp-Cys

SEQ ID NOiG3
LENGTHiG13
TYPEiGPRT
ORGANISMiGCanis familiaris
SEQUENCEiGPb2
Leu-Phe-Leu-Ser-Asn-Leu-Ser-Phe-Ser-Asp-Leu-Cys-Ala

Please consult.

<110> Smith, John; Smithgene Inc.

<120> Example of a Sequence Listing

<130> 01-00001

<140> PCT/EP98/00001
<141> 1998-12-31

<150> US 08/999,999
<151> 1997-10-15

<160> 6

<170> PatentIn version 2.0

<210> 1
<211> 389
<212> DNA
<213> Paramecium sp.

<220> CDS
<221> (279)...(389)
<222>

<300>
<301> Doe, Richard
<302> Isolation and Characterization of a Gene Encoding a
Protease from Paramecium sp.
Journal of Genes

<303> 1
<304> 1
<305> 4
<306> 1-7
<307> 1988-06-31
<308> 123456
<309> 1988-06-31

<400>	1						60
agctgtagtc	attcctgtgt	cctcttctct	ctgggcttct	cacctgcta	atcagatctc		
agggagagtg	tcttgacctt	cctctgcctt	tgcagcttca	caggcaggca	ggcaggcagc		120
tgatgtggca	attgctggca	gtgccacagg	cttttcagcc	aggcttaggg	tgggttccgc		180
cgcggcgcg	cggccctctt	cgcgtctctc	tcgcgcctct	ctctcgtctc	cctctcgtct		240

Appendix 3, page 2

ggacctgatt aggtgagcag gaggagggggg cagtttagc atg gtt tca atg ttc agc 296
Met Val Ser Met Phe Ser

ttg tct ttc aaa tgg cct gga ttt tgt ttg ttt gtt tgt ttg ttc caa 344
Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Cys Leu Phe Gln

tgt ccc aaa gtc ctc ccc tgt cac tca tca ctg cag ccg aat ctt 389
Cys Pro Lys Val Leu Pro Cys His Ser Ser Leu Gln Pro Asn Leu

<210> 2
<211> 37
<212> PRT
<213> Paramecium sp.

<400> 2
Met Val Ser Met Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu
1 5 10 15

Phe Val Cys Leu Phe Gln Cys Pro Lys Val Leu Pro Cys His Ser Ser
20 25 30

Leu Gln Pro Asn Leu
35

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

<400> 3
Met Val Asn Leu Glu Pro Met His Thr Glu Ile
1 5 10

<210> 4
<400> 4
000

[Annex VIII follows]

identifiers and their accompanying information as shown in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	M
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M, when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	M
<170>	Software	Name of software used to create the Sequence Listing	O
<210>	SEQ ID NO: #:	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer M expressing the number of bases or amino acid residues	M

<212>	Type	Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.	M
<213>	Organism	Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.	
<220>	Feature	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221>	Name/Key	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence
<222>	Location	Specify location within sequence; where appropriate state number of first and last bases/amino acids	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

in feature

se was used in
sequence

<223>

Other Inform-
ation

Other relevant
information;
four lines maximum

M, under the fol-
lowing conditions:
if "n," "Xaa," or
a modified or un-
usual L-amino acid
or modified base
was used in a
sequence; if
ORGANISM
is "Artificial
Sequence" or
"Unknown"; if
molecule is com-
bined DNA/RNA.

<300>

Publication
Information

Leave blank
after <300>

0

<301>

Authors

Preferably max
of ten named
authors of publi-
cation; specify
one name per line;
preferable format:
Surname, Other
Names and/or
Initials

0

<302>

Title

0

<303>

Journal

0

<304>

Volume

0

<305>

Issue

0

<306>

Pages

0

<307>

Date

Journal date on which
data published;
specify as yyyy-mm-
dd, MM-yyyy or
Season-yyyy

0

<308>

Database
Accession
Number

Accession number
assigned by data-
base including
database name

0

<309>

Database Entry
Date

Date of entry in
database; specify
as yyyy-mm-dd or
MM-yyyy

0

<310>

Patent Document
Number

Document number;
for patent-type
citations only.
Specify as, for
example, US
07/999,999

0

<311>	Patent Filing Date	Document filing date, for patent-type citations only; specify as yyyy-mm-dd	0
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd	0
<313>	Relevant Residues	FROM (position) TO (position)	0
<400>	Sequence	SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence	M

5. Section 1.024 is revised to read as follows:

1.024 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.021(c) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;